Author:
Khashei Varnamkhasti Khalil,Khashei Varnamkhasti Samire,Shahrouzian Atefeh,Rahimzadeh Masoomeh,Naeimi Leila,Naeimi Behrouz,Naeimi Sirous
Abstract
Abstract
Background
The apparent lack of additional missense mutations data on mixed-phenotype leukemia is noteworthy. Single amino acid substitution by these non-synonymous single nucleotide variations can be related to many pathological conditions and may influence susceptibility to disease. This case-control study aimed to unravel whether the ZAP70 missense variant (rs104893674 (C > A)) underpinning mixed-phenotype leukemia.
Methods
The rs104893674 was genotyped in clients who were mixed-phenotype acute leukemia-, acute lymphoblastic leukemia- and acute myeloid leukemia-positive and matched healthy controls, which have been referred to all major urban hospitals from multiple provinces of country- wide, IRAN, from February 11’ 2019 to June 10’ 2023, by amplification refractory mutation system-polymerase chain reaction method. Direct sequencing for rs104893674 of the ZAP70 gene was performed in a 3130 Genetic Analyzer.
Results
We found that the AC genotype of individuals with A allele at this polymorphic site (heterozygous variant-type) contribute to the genetic susceptibility to acute leukemia of both forms, acute myeloid leukemia and acute lymphoblastic leukemia as well as with a mixed phenotype. In other words, the ZAP70 missense variant (rs104893674 (C > A)) increases susceptibility of distinct cell populations of different (myeloid and lymphoid) lineages to exhibiting cancer phenotype. The results were all consistent with genotype data obtained using a direct DNA sequencing technique.
Conclusion
Of special interest are pathogenic missense mutations, since they generate variants that cause specific molecular phenotypes through protein destabilization. Overall, we discovered that the rs104893674 (C > A) variant chance in causing mixed-phenotype leukemia is relatively high.
Publisher
Springer Science and Business Media LLC
Reference25 articles.
1. Bhalodia JN, Patel MM. Profile of Pediatric Malignancy: A three-year study. Nat J Community Med. 2011;2(1):24–7.
2. George B, Gonzalez A, Rios A. Inside the Biology of Acute Leukemias of Ambiguous Lineage: Diagnostic Work-Up, genomic and clinical characterization. J Cancer Sci Clin. 2022;6(3):276–80.
3. Eckstein OS, Wang L, Punia JN, Kornblau SM, Andreeff M, Wheeler DA. Mixed-phenotype acute leukemia (MPAL) exhibits frequent mutations in DNMT3A and activated signaling genes. Exp Hematol. 2016;44(8):740–4.
4. Khan M, Siddiqi R, Naqvi K. An update on classification, genetics, and clinical approach to mixed phenotype acute leukemia (MPAL). Ann Hematol. 2018;97:945–53.
5. Alexander TB, Orgel E. Mixed phenotype Acute Leukemia: current approaches to diagnosis and treatment. Curr Oncol Rep. 2021;23(2):22.